Study Summary
This trial will compare the effects of two cancer treatments in people with EGFR-mutated NSCLC that has progressed despite treatment with osimertinib.
- Cancer
- Non-Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 10 Secondary · Reporting Duration: Approximately 55 months post first subject randomized
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Chemotherapy
1 of 2
Savolitinib + Osimertinib
1 of 2
Active Control
Experimental Treatment
324 Total Participants · 2 Treatment Groups
Primary Treatment: Savolitinib · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 130 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
When might Savolitinib be cleared for public use in the United States?
"Savolitinib was given a safety score of 3. This is because it is a Phase 3 trial, so there is already some evidence that the drug works and that it doesn't cause too many adverse effects." - Anonymous Online Contributor
Are there several hospitals running this study in different cities?
"To make participating in this trial as convenient as possible for patients, the locations have been spread out across 14 different sites. Some of these include Nashville, Orlando and Evergreen Park." - Anonymous Online Contributor
Are those under the age of 65 years old able to participate in this research?
"This study includes patients that are aged 18 or older, with the maximum age limit set at 130 years old." - Anonymous Online Contributor
Which patients would be a good fit for this clinical trial?
"This study is enrolling 324 people with carcinoma aged 18 and 130. Most notable, patients are required to meet the following criteria: • Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.• Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.• Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.• Mandatory provision of FFPE tumour" - Anonymous Online Contributor
Are researchers looking for more participants in this trial?
"This trial is still recruiting patients, if you are interested. The listing on clinicaltrials.gov shows that the study was first posted on 8/3/2022 and has been edited most recently on 11/7/2022." - Anonymous Online Contributor
How many people are enrolled in the trial?
"In order to move forward with this study, we need 324 individuals who meet the pre-determined inclusion criteria. These patients will be recruited from different locations such as Research Site in Nashville, Tennessee and Rutgers Cancer Institute of New Jersey (CINJ) in Orlando, Illinois." - Anonymous Online Contributor